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Studies evaluating molecular profiles of breast cancer indicate that breast tumors can be classified into five clinically relevant subtypes on the basis of gene expression patterns (1, 2): luminal A, luminal B, HER2-overexpressing, basal-like, and unclassified. Expression of the estrogen receptor (ER), progesterone receptor (PR), and HER2-neu (HER2) alone can be used to approximately differentiate between these subtypes (3, 4). Luminal A and B tumors are ER+, while HER2-overexpressing tumors are hormone receptor-negative but overexpress HER2 (i.e., ER-/PR-/HER2+).  Basal-like and unclassified tumors both have a ‘triple-negative’ phenotype (i.e., ER-/PR-/HER2-), although approximately 70% of triple-negative tumors are basal-like (5).
Existing data point to a distinct biology of non-luminal (ER-) breast tumors.  Non-luminal tumors are more likely than luminal tumors to present at an advanced stage and to have a high grade (4, 6, 7).  While luminal tumors are most likely to be responsive to hormonal therapies, such as tamoxifen, and HER2-overexpressing tumors respond favorably to treatment with trastuzumab, therapeutic options for triple-negative tumors are limited and non-specific (8). Consistent with these differences, there are marked differences in survival between luminal, HER2-overexpressing, and triple-negative breast cancers (2, 4, 8-10).  Luminal subtypes are associated with the most favorable prognoses (90% five-year disease-specific survival) (2, 4).  Five-year disease-specific survival rates are only 20-75% for HER2-overexpressing tumors, 30-80% for basal-like tumors, and 50-85% for unclassified tumors (2, 4).  Although HER2-overexpressing and triple-negative tumors account for <30% of all breast cancers (4, 11), furthering our understanding of the etiologies of these tumors is particularly important given their relatively poor prognoses.  
Although the clinical relevance of these molecular subtypes of breast cancer is evident, etiologic differences between subtypes have not been well studied.  Studies suggest that basal-like tumors are more common among African-American women (4, 7, 12), premenopausal women (4, 11), and women with a family history of breast cancer (11), specifically BRCA1 mutation carriers (13).  However, few studies have evaluated differences in the associations between established breast cancer risk factors and molecular subtypes of breast cancer defined by joint ER/PR/HER2 status.
The focus of this study is on the relationship between anthropometric characteristics and risk of breast cancer subtypes defined by ER/PR/HER2 status.  It is well established that obesity, particularly among postmenopausal non-users of hormone therapy (HT), is positively related to risk of breast cancer (14-16).  This relationship is thought to be hormonally mediated given the positive correlation between obesity and endogenous estrogen levels (17-19).  Given proposed mechanisms and data from prior studies indicating that the association between body mass index (BMI) and postmenopausal breast cancer risk is stronger for hormone receptor-positive disease than hormone receptor-negative disease (20-22), it is reasonable to hypothesize that obesity would be more strongly related to risk of luminal breast tumors.  However, non-hormonal factors such as cytokine levels and genetic factors may also contribute to the association between BMI and breast cancer risk, and these factors might contribute to risk of either luminal, HER2-overexpressing, or triple-negative tumors (23-26).  Of the two prior studies to have evaluated the relationship between anthropometric characteristics and risk of molecular subtypes of breast cancer (11, 27), the larger study (n=172 triple-negative cases) observed that waist-to-hip ratio (WHR), a measure of central obesity, was more strongly related to risk of triple-negative disease than to other subtypes (27).  While neither study observed an association between BMI and postmenopausal triple-negative breast cancer, neither stratified results by HT use.  

METHODS
		Given the rarity of HER2-overexpressing and triple-negative tumors, cases and controls were pooled from two population based case-control studies of breast cancer.  Both studies were approved by the Fred Hutchinson Cancer Research Center (FHCRC) institutional review board, and written informed consent was obtained from all study participants.  In both studies, cases were identified through the Cancer Surveillance System (CSS) of western Washington State as women with incident invasive breast cancer who had no prior history of in situ or invasive breast cancer and were residents of King, Pierce, or Snohomish counties.  Both studies have been described in detail elsewhere (28, 29).  Briefly, cases were eligible for the earlier study if they were diagnosed with breast cancer between April 1, 1997 and May 31, 1999, were aged 65-79 years at diagnosis, and had a Health Care Financing Administration (HCFA) record (28).  Potential controls without a prior breast cancer were identified through HCFA records and frequency matched to cases on age.  80.6% (n=975) of eligible cases and 73.6% (n=1,007) of eligible controls were enrolled and completed the study interview.  Cases were eligible for the more recently completed study if they were diagnosed with invasive breast cancer between January 1, 2000 and March 31, 2004, and were aged 55-74 years at diagnosis (29).  All incident lobular breast cancer cases and a 25% random sample of incident ductal cases were eligible.  Women diagnosed with breast cancers that were neither ductal nor lobular were excluded.  Controls were identified through random-digit dialing (30) and frequency matched to cases on age.  83.5% (n=1,044) of eligible cases and 71.1% (n=469) of eligible controls were enrolled and completed the study interview.  This analysis was restricted to ductal cases from both studies (n=1,233) because the only other histological type of breast cancer included in the more recent study was lobular carcinoma, and HER2-overexpressing and triple-negative tumors are very rarely lobular.  Specifically, >92% of lobular carcinomas are ER+ (i.e., luminal) (31). Thus, because risk factors for lobular breast cancer differ from those for ductal disease (32) and lobular breast cancer cases were oversampled in the more recent of the two pooled studies, inclusion of lobular cases in this analysis could have skewed subtype-specific associations.  Histological classifications were based on centralized reviews of pathology reports for all cases.
Both studies utilized nearly identical protocols and materials, and used very similar questionnaires that were administered in-person.  Both questionnaires included information on a wide range of breast cancer risk factors including medical history, demographics, reproductive history, hormone use, lifestyle factors, and family history of cancer.  Women were asked about exposures occurring before their reference date, defined as the date of diagnosis for cases; control reference dates were assigned based on the expected distribution of case reference dates.  Both studies collected physical measurements for weight and height at the time of the interview, and self-reported measures for height, weight at reference year, maximum lifetime weight, and weight at age 30.  Adult weight change was defined as the difference between self-reported weight in the reference year and self-reported weight at age 30 years.  BMI in the reference year was estimated based on measured height and self-reported weight in the reference year.  When measured height was not available, self-reported height was used (5% of cases, 4% of controls).  Similarly, measured weight was used when self-reported weight was not provided (1% of cases, 1% of controls).  A high level of agreement was observed between self-reported and measured anthropometric characteristics (r=0.87 for height and r=0.93 for weight) and between quartile categorizations of self-reported and measured body size (r=0.81 for height, r=0.89 for weight).
		ER and PR data were identified from CSS records, while data on HER2 expression status data was taken from centralized pathology testing at the Fred Hutchinson Cancer Research Center (completed for 411 ductal cases from the more recent study) and CSS records (reviewed for all cases).  If HER2 data were available from both sources and were discrepant, CSS results were given primacy because such results were based on the original diagnostic testing that utilized complete specimens, whereas centralized testing at the FHCRC research laboratory utilized the tissue remaining after clinical workup.  A total of 401 (33%) cases were missing data for at least one tumor marker: 52 (4%) cases had missing ER status, 53 (4%) had missing PR status, and HER2 status could not be determined for 386 (31%) cases.  All ER and PR results, and most HER2 results, were based on immunohistochemistry (IHC) testing.  However, CSS records of fluorescence in situ hybridization (FISH) testing for HER2 were available for 32 cases.  When available, FISH results were given precedence over IHC results.  Cases were classified as HER2 negative if their FISH test was negative or they had an IHC score of 0, 1+, or 2+, and were classified as HER2 positive if their FISH test was positive or they had an IHC score of 3+.  Clinically, an IHC score of 2+ is considered indeterminate and warrants a confirmatory FISH test.  In the absence of FISH testing for cases with 2+ IHC results for HER2 (n=80), we classified 2+ results as HER2 negative because of data indicating that 80% of these tumors are HER2 negative when tested by FISH (33, 34).  Since all ER+ cases were classified as luminal regardless of HER2 status (see below), we conducted sensitivity analyses that only excluded the 5 triple-negative cases that were ER-/PR- and had a 2+ HER2 status without a FISH result.  Since our results did not change with this exclusion, and to be consistent with prior studies (4), all ER-/PR- cases with an HER2 IHC result of 2+ without FISH confirmation were included as triple-negative cases in our final analyses.
Classification of tumor subtypes was based on ER, PR, and HER2 data as follows, consistent with the criteria used by Carey et al. (4): luminal (ER+), HER2-overexpressing (ER-/PR-/HER2+), and triple-negative (ER-/PR-/HER2-).  Prior studies have sub-classified luminal tumors as luminal A or luminal B; however, because these luminal subtypes are clinically similar and not well distinguished on the basis of only ER, PR, and HER2 status (4), all luminal tumors were grouped together in this analysis.  Prior studies have also sub-classified triple-negative tumors as basal-like or unclassified based on EGFR and cytokeratin 5/6 expression (4, 11), but because EGFR and cytokeratin 5/6 expression data were not available for the present analysis, we grouped together all triple-negative tumors; however, given that approximately 70% of triple-negative breast tumors are basal-like (5), the triple-negative phenotype has previously been utilized as an approximation of the basal-like subtype (12, 35).  
Cases missing ER expression data (n=52) and cases who were ER-/PR- but were missing HER2 data (n=32) were excluded as we were unable to classify these cases as luminal, HER2-overexpressing, or triple-negative.  However, cases excluded due to insufficient tumor marker data did not significantly differ from other cases with respect to body size measurements, including BMI in the reference year [27.3 kg/m2 vs. 28.1 kg/m2, respectively (p-value=0.29)], height [162.0 cm vs. 161.3 cm (p-value=0.40)], and BMI at age 30 [22.6 kg/m2 vs. 22.9 kg/m2 (p-value=0.46)], or with regard to the prevalence of current HT use [46% vs. 48% (p-value=0.75)].  All cases that were ER-/PR+ were also excluded due to the rarity of this phenotype (n=9).  After excluding individuals with insufficient tumor marker data or incomplete anthropometric data, final analyses were based on 1,447 controls and 1,124 cases [1,008 (90%) luminal, 39 (3%) HER2-overexpressing, and 77 (7%) triple-negative].
Polytomous logistic regression (36) was used to compare luminal, HER2-overexpressing, and triple-negative case groups to a common control group.  Body size measures were analyzed both continuously and as categorical variables, with categories defined according to the quartile distribution in controls; BMI was also analyzed using categories based on the National Heart Blood and Lung Institute (NHLBI) definitions for normal weight (BMI <25.0 kg/m2), overweight (BMI 25.0-29.9 kg/m2), and obese (BMI ≥30 kg/m2) (37).  Since HT use is an established effect modifier of the relationship between obesity and risk of breast cancer among postmenopausal women (14, 15), we evaluated interactions between current use of HT (never use vs. current use) and both BMI and weight in relation to breast cancer risk through the inclusion of interaction terms.  All analyses were adjusted for age (continuous) and reference year (continuous); because there was no overlap in reference years between the two pooled studies, adjustment for reference year resulted in implicit adjustment for study population.  The following breast cancer risk factors were evaluated as potential confounders with respect to the two largest case groups, luminal and triple-negative: education level (≤ high school degree / post-high school  / college graduate), age at menarche (≤11 / 12-13 / ≥14), age at menopause (<50 / 50-54 / ≥55), current HT use (no / estrogen only / estrogen + progestin), family history of breast cancer in first degree relatives (yes / no), parity (nulliparous / parous), age at first live birth (nulliparous / <25 / ≥25), smoking status (yes / no), and alcohol consumption (non-drinker / ≤7 drinks per week / >7 drinks per week).  Adjustment for these potential confounders did not alter our risk estimates by more than 10% for either tumor subtype.  The exception to this was that the association between BMI and risk of triple-negative disease among current HT users was altered by slightly greater than 10% with adjustment for alcohol consumption, but did not alter the risk of luminal disease.  Therefore, none of these factors were included in the final analyses as confounders.  Heterogeneity of effect estimates between case groups was examined through a series of polytomous regression models comparing HER2-overexpressing and triple-negative case groups to the luminal case group.  All statistical analyses were performed using STATA/SE version 8.2 (StataCorp, College Station, Texas).

RESULTS
	Relative to other cases and controls, women with triple-negative breast cancer were slightly younger and more likely to have never used HT (Table 1).  Luminal cases were more likely to have a first-degree family history of breast cancer and to be current users of combined estrogen plus progestin HT.  HER2-overexpressing cases were less likely to be college graduates and to have had their first live birth before age 20.
Associations with BMI and weight at the reference date varied by tumor subtype (Table 2).  Overall, we did not find BMI to be related to risk of either luminal, HER2-overexpressing, or triple-negative disease, although there was a suggestion that women in the highest BMI quartile had an elevated risk of triple-negative disease compared to women in the lowest quartile (OR=1.7, 95% CI: 0.9-3.3, p-value = 0.12).  However, stratification by HT use (non-users vs. current users) indicated an association between BMI and breast cancer risk for luminal and triple-negative subtypes confined to women who were not current HT users [OR comparing highest vs. lowest quartiles=1.7, 95% CI: 1.2-2.4 (p-value < 0.01) for the luminal subtype and OR=2.7, 95% CI: 1.0-7.5 (p-value = 0.05) for the triple-negative subtype].  Effect modification by current HT use was also evident when BMI was analyzed as a categorical variable with categories defined by NHLBI cutpoints for normal / overweight / obese.  However, among non-users of HT, effect estimates for breast cancer risk in obese women relative to women of normal BMI were not statistically significant and were smaller in magnitude than those observed when comparing women in the highest vs. lowest quartiles of BMI [OR=1.3, 95% CI: 1.3-1.7 (p-value=0.10) for the luminal subtype and OR=1.7, 95% CI: 0.8-3.6 (p-value=0.19) for the triple-negative subtype].  Similar to observations with regard to BMI, among non-users of HT, women in the highest weight quartile had a 5.1-fold (95% CI: 1.1-23.0, p-value = 0.03) increased risk of triple-negative breast cancer and a 1.7-fold (95% CI: 1.2-2.4, p-value < 0.01) increased risk of luminal breast cancer compared to those in the lowest quartile.  With respect to triple-negative disease, however, there was no linear trend or dose-response of increasing risk with increasing weight or BMI; in fact, effect estimates comparing women in the second lowest quartile to women in the lowest quartile were similar or larger in magnitude than those comparing women in the highest vs. lowest quartiles of weight or BMI.  When analyzed as continuous terms, weight and BMI were positively associated with breast cancer risk only among non-users of HT, and these associations were statistically significant only for luminal disease [OR=1.01, 95% CI: 1.00-1.02 (p-value <0.01) and OR=1.03, 95% CI: 1.01-1.05 (p-value <0.01), respectively], although ORs were similar but not statistically significant for both triple-negative and HER2-overexpressing case groups. 
Although not statistically significant, women in the highest lifetime weight quartile, women in the highest weight at age 30 quartile, and women in the tallest height quartile had 1.9-fold, 1.5-fold, and 1.5-fold, respectively, elevated risks of triple-negative tumors, compared to 1.2-fold, 1.1-fold, and 1.2-fold elevated risks of luminal tumors, respectively (Table 3).  However, all of these estimates were within the limits of chance.  Women who self-reported a lower weight in the reference year than at age 30 had a significantly reduced risk of luminal breast cancer relative to women in the lowest tertile of weight gain [OR=0.5, 95% CI: 0.3-0.6] and a similarly reduced (but not statistically significant) risk of HER2-overexpressing disease [OR=0.5, 95% CI: 0.1-1.8]; this measure was not, however, associated with risk of triple-negative breast cancer.  When analyzed as continuous terms, lifetime maximum weight was positively associated with risk of luminal and triple-negative tumors [OR=1.00, 95% CI: 1.00-1.01 (p-value=0.02) and OR=1.01, 95% CI: 1.00-1.01 (p-value=0.04), respectively] and adult weight change was associated with risk of positively associated with risk of luminal tumors [OR=1.01, 95% CI: 1.00-1.01 (p-value<0.01)].  BMI at age 30 and lifetime maximum BMI were not associated with risk of any disease subtype.  None of the factors assessed were strongly related to risk of HER2-overexpressing tumors, although these analyses were limited by the inclusion of only 39 HER2-overexpressing cases.

DISCUSSION
It is important to acknowledge the limitations of this study before interpreting our results.  We had to exclude 84 (7%) eligible cases because they were missing sufficient tumor marker data to be categorized into a molecular subtype.  However, cases that could not be classified did not differ markedly from other cases with respect to height, weight, or BMI at the reference year.  We therefore assume that the exclusion of cases with insufficient tumor marker data did not differentially bias study findings.  Another limitation is the lack of information on other tumor markers that would have enabled us to more precisely classify case groups.  Specifically, without data on EGFR or cytokeratin 5/6 expression, we were unable to distinguish between basal-like and unclassified tumors within our triple-negative case group (3).  While this distinction appears to be significant with respect to overall survival and therapeutic response (4, 38), findings from the PBCS (11) and the CBCS (27) do not indicate substantial differences in the epidemiologies of basal-like triple-negative and unclassified triple-negative tumors; thus, we anticipate that the distinction between basal-like and unclassified tumors may be more important in clinical settings than in the context of epidemiologic studies.  Misclassification of case subtypes may also result from the use of tumor marker data from multiple laboratories in the Seattle-Puget Sound region, given that assays and practices for interpreting results vary across institutions.  While a certain degree of misclassification of tumor subtype is present due to these differences, it is reasonable to assume that this misclassification is non-differential with respect to anthropometric factors and would have biased our risk estimates toward the null.  Lastly, this analysis included limited numbers of triple-negative and HER2-overexpressing cases; as such, some categories of the anthropometric characteristics contained very few cases and resulting effect estimates need to be interpreted with caution.  The observed small numbers for triple-negative and HER2-overexpressing cases reflect the rarity of these tumor types relative to luminal breast cancers overall and the fact that we had to exclude a number of non-luminal cases due to missing HER2 data (n=32).  Additionally, the distribution of these subtypes is reflective of the demographic characteristics of our study population.  Specifically, existing data suggest that non-luminal breast cancers, particularly triple-negative cancers, are associated with African-American and Hispanic white race/ethnicity and early age at diagnosis (12, 27, 39).  Thus, the fact that the studies pooled for this analysis involved populations that were predominantly non-Hispanic white (92%) and exclusively postmenopausal likely contributed to the observed low prevalence of the triple-negative and HER2-overexpressing phenotypes.  Given that only 4% and 2% of cases eligible for the earlier and more recently completed studies, respectively, died before an interview could be conducted, we assume that survivor bias did not appreciably influence the distribution of case subtypes, even though non-luminal breast cancers are associated with a less favorable prognosis than luminal disease (2, 4, 8-10).    
Limitations to this study may also exist with regard to the ascertainment and classification of exposures.  In particular, misclassification of exposure categories might have occurred if women were unable to accurately recall or report their weight in the reference year or at age 30.  Although we measured the weight of cases and controls at the time of the interview, self-reported weight data were given primacy over actual measurements due to the fact that interviews were conducted up to three years after breast cancer diagnosis, and cancer treatments could have contributed to weight changes during that intervening period.  Additionally, our analyses could be biased if women who participated in these studies differed from those who did not participate with regard to body size.
Our results suggest that there may be heterogeneity in the associations between anthropometric measures and postmenopausal breast cancer risk by tumor subtype, although differences between subtypes were not statistically significant.  Consistent with prior studies that assessed the association between BMI and breast cancer risk by joint ER/PR status (21, 22, 40-44), we observed that BMI was positively associated with risk of luminal (i.e., ER+) breast cancer among postmenopausal women not using HT.  This association is likely largely attributable to the positive relationship between BMI and endogenous estrogen levels since adipose tissue is the primary source of estrogen in postmenopausal women.  However, we found that among non-users of HT, postmenopausal BMI and weight may also be related to risk of triple-negative breast cancer.  Due to the small numbers of triple-negative cases in the lowest weight and BMI quartiles, and given the lack of a clear dose-response or linear trend in effect estimates with increasing weight or BMI, we cannot rule out the possibilities that these may be chance findings or may reflect particularly low risks among persons with a low weight or BMI, rather than reflecting an elevated risk among persons with a high weight or BMI.
Only two prior population-based studies, the Polish Breast Cancer Study (PBCS) (11) and the Carolina Breast Cancer Study (CBCS) (27), have assessed differences in breast cancer risk factors among non-luminal breast cancer subtypes.  Similar to our study, these analyses were based on large overall case populations (n=804 for the PBCS and n=1,424 for the CBCS), but included limited numbers of postmenopausal non-luminal cases (n=99 and n=172 postmenopausal triple-negative cases, respectively, and n=47 and n=70 postmenopausal HER2-overexpressing cases).  Neither study observed an association between BMI and risk of basal-like or unclassified triple-negative breast cancer among postmenopausal women, but neither study presented estimates stratified by HT use.  To our knowledge, there are no previously published data on the relationship between height,  weight, or weight gain and risk of triple-negative or HER2-overexpressing tumors.  The CBCS did, however, identify a significant positive association between waist-hip ratio (WHR) and risk of postmenopausal basal-like breast cancer (OR for highest vs. lowest tertile = 2.7, 95% CI: 1.3-5.4).  Given that most postmenopausal weight gain is central weight gain (45), our finding of no association between adult weight gain and risk of triple-negative breast cancer is not entirely consistent with the finding of the CBCS with respect to WHR; however, this might be attributable to small numbers in both studies or to differences in the distribution of race/ethnicity between studies contributing to differences in adiposity patterns.
The observed associations between BMI and weight and risk of triple-negative breast cancer among non-users of HT are somewhat unexpected given the predominating theory that the effects of anthropometric factors on postmenopausal breast cancer risk are mediated through hormonal pathways.  The possibility that hormonal mechanisms may underlie the etiology or promotion of triple-negative breast tumors is consistent with the findings of two recent studies.  The Breast and Prostate Cancer Cohort Consortium recently reported that two haplotypes of the 17-hydroxysteroid dehydrogenase 1 gene (17HSD1), which catalyses the final step of the conversion of estrone to estradiol, were associated with risk of ER- but not ER+ breast tumors (46).  Additionally, Gupta et al. used a xenograft mouse-model to demonstrate that ER- tumors required circulating estrogens for their formation; this study suggested that estrogens may effect the growth of ER- tumors by enhancing angiogenesis and stromal cell recruitment to promote tumor growth (47).
Non-hormonal mechanisms underlying the association between postmenopausal breast cancer and anthropometric factors have not been well elucidated, although it has been suggested that obesity may be associated with insulin resistance and increased concentrations of insulin, which may have a mitogenic effect on breast tumors (24, 26).  Observed associations between anthropometric factors and breast cancer may also be reflective of the increased levels of leptin (48) and markers of inflammation associated with obesity, such as tumor necrosis factor  and IL-6 (49).  Specifically, elevated leptin levels in obese women may increase breast cancer risk through angiogenic effects (48) while obesity-associated chronic inflammation may increase risk through the activation of redox-sensitive transcription factors such as nuclear factor kappa B (50). 
It is also important to note that grouping cases according to joint ER/PR/HER2 status assumes that the combination of these markers is of greater relevance with respect to anthropometric risk factors than each marker independently.  However, at least one prior study has suggested that HER2 status may be inversely associated with BMI independent of ER status (51).  Overall, we found no difference in associations with height, weight, or BMI by HER2 status, although comparison of BMI and of weight among non-users of HT revealed slightly, but not significantly stronger effect estimates with respect to HER2- breast cancer than with respect to HER2+ breast cancer [OR comparing highest vs. lowest quartiles of BMI=1.8, 95% CI: 1.2-2.6 and OR=0.9, 95% CI: 0.5-1.8, respectively (p-value for heterogeneity=0.09); OR comparing highest vs. lowest quartiles of weight=1.8, 95% CI: 1.2-2.6 and OR=1.0, 95% CI: 0.5-2.1, respectively (p-value for heterogeneity=0.17)].  Given that approximately 89% of luminal cases with known HER2 expression status were HER2-, the fact that we observed similar effect estimates with respect to luminal and triple-negative but not the HER2-overexpressing case groups is consistent with a role of HER2 independent of ER.  Additional studies with sufficient numbers of HER2+ and HER2- tumors would help clarify the association between HER2 expression status and BMI.
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TABLE 1.  Distributions of demographic characteristics and established breast cancer risk factors among controls and luminal, HER2-overexpressing, and triple-negative cases
		Cases
	Controls(n=1,447)n (%)	Luminal(ER+)(n=1,008)n (%)	HER2-Overexpressing (ER-/PR-/HER2+)(n=39)n (%)	Triple-Negative(ER-/PR-/HER2-)(n=77)n (%)
Age, years  55-59  60-64  65-69  70-74  75-79  Mean	131 (9)119 (8)440 (30)470 (32)287 (20)69.3	120 (12)106 (11)275 (27)332 (33)175 (17)68.6	5 (13)7 (18)10 (26)9 (23)8 (21)67.6	16 (21)12 (16)27 (35)12 (16)10 (13)66.0
Race/ethnicity  Non-Hispanic White  African American  Asian/Pacific Islander  Hispanic White  Other	1323 (91)42 (3)38 (3)25 (2)19 (1)	945 (94)16 (2)29 (3)8 (1)10 (1)	32 (82)2 (5)3 (8)2 (5)0 (0)	71 (92)3 (4)1 (1)1 (1)1 (1)
Education   High school or less  Some college  College graduate	682 (47)460 (32)304 (21)	441 (44)332 (33)235 (23)	18 (46)17 (44)4 (10)	33 (43)28 (36)16 (21)
First-degree family history of breast cancer  No  Yes  Missing	1131 (83)226 (17)90	727 (77)219 (23)38	33 (85)6 (15)0	61 (87)9 (13)7 
Hormone therapy use  Never use  Former use  Current use of unopposed estrogen   Current use of estrogen+progestin   Missing	539 (37)247 (17)450 (31)207 (14)4	340 (34)165 (17)246 (25)246 (25)11	10 (27)11 (30)10 (27)6 (16)2	32 (42)13 (17)21 (27)11 (14)0
Parity  0  1  2  3  ≥ 4	125 (9)114 (8)346 (24)389 (27)473 (33)	113 (11)93 (9)267 (26)256 (25)279 (28)	3 (8)4 (10)16 (41)4 (10)12 (31)	7 (9)9 (12)21 (27)18 (23)22 (29)





TABLE 2.  Age-adjusted odds ratios for body mass index (BMI) and weight by tumor subtype and current HT use
 
	Controls	Luminal cases	HER2-overexpressing cases	Triple-negative cases
	n (%)	n (%)	OR* (95% CI)	n (%)	n (%)	n (%)	OR* (95% CI)





	Controls	Luminal cases	HER2-overexpressing cases	Triple-negative cases
	n (%)	n (%)	OR* (95% CI)	n (%)	n (%)	n (%)	OR* (95% CI)
Weight, lbsOverall   Quartiles: < 121                    121-139                    140-162                    > 162Trend test   Continuous (per lb):No current HT use   Quartiles: < 121                   121-139                   140-162                   > 162Trend test   Continuous (per lb):Current HT use   Quartiles: < 121                    121-139                    140-162                    > 162Trend test   Continuous (per lb):	366 (25)380 (26)346 (24)355 (25)188 (24)205 (26)176 (22)215 (27)178 (27)175 (26)170 (26)140 (21)	200 (20)285 (28)250 (25)273 (27)82 (16)134 (26)133 (26)166 (32)118 (24)151 (31)117 (24)107 (22)	1.0 (ref)1.3 (1.1-1.7)†1.3 (1.0-1.6)1.3 (1.1-1.7)†p = 0.041.01 (1.00-1.01)†1.0 (ref)1.5 (1.1-2.1)†1.7 (1.2-2.4)†1.7 (1.2-2.4)†p < 0.011.01 (1.01-1.02)†1.0 (ref)1.2 (0.9-1.7)1.0 (0.7-1.4)1.1 (0.8-1.5)p = 0.971.00 (0.99-1.01)	8 (21)11 (28)7 (18)13 (33)5 (22)7 (30)2 (9)9 (39)3 (19)4 (25)5 (31)4 (25)	1.0 (ref)1.3 (0.5-3.2)0.9 (0.3-2.4)1.5 (0.6-3.7)p = 0.501.01 (0.99-1.03)1.0 (ref)1.2 (0.4-4.0)0.4 (0.1-2.1)1.4 (0.4-4.3)p = 0.791.01 (0.98-1.03)1.0 (ref)1.2 (0.3-5.6)1.5 (0.4-6.6)1.5 (0.4-6.7)p = 0.541.00 (0.97-1.04)	9 (13)26 (33)19 (24)23 (31)2 (4)17 (38)11 (24)15 (33)7 (22)9 (28)8 (25)8 (25)	1.0 (ref)2.5 (1.2-5.4)†1.9 (0.9-4.4)2.1 (1.0-4.7)p = 0.201.01 (1.00-1.02)1.0 (ref)7.2 (1.6-31.6)†5.1 (1.1-23.7)†5.1 (1.1-23.0)†p = 0.181.01 (0.99-1.03)1.0 (ref)1.1 (0.4-3.2)1.0 (0.3-2.8)1.2 (0.4-3.3)p = 0.871.01 (0.98-1.03)


TABLE 3: Age-adjusted odds ratios for quartiles of other anthropometric characteristics by tumor subtype

	Controls	Luminal cases	HER2-overexpressing cases	Triple-negative cases
	n (%)	n (%)	OR* (95% CI)	n (%)	OR* (95% CI)	n (%)	OR* (95% CI)
Height, cm   Quartiles: < 157                   157-160                   161-165                   > 165Trend test   Continuous (per cm):	362 (25)362 (25)395 (27)328 (23)	222 (22)227 (23)301 (30)258 (26)	1.0 (ref)1.0 (0.8-1.3)1.2 (1.0-1.5)1.2 (1.0-1.5)p = 0.051.01 (1.00-1.02)	11 (28)10 (26)11 (28)7 (18)	1.0 (ref)0.9 (0.4-2.1)0.9 (0.4-2.0)0.6 (0.2-1.6)p = 0.341.00 (0.95-1.05)	13 (17)15 (19)26 (34)23 (30)	1.0 (ref)1.1 (0.5-2.3)1.6 (0.8-3.3)1.5 (0.7-3.1)p = 0.131.02 (0.98-1.05)
Lifetime maximum BMI, kg/m2   Quartiles: < 25.0                    25.0-27.9                    28.0-32.3                    > 32.3Trend test   Continuous (per kg/m2): 	362 (25)361 (25)363 (25)361 (25)	235 (23)241 (24)261 (26)271 (27)	1.0 (ref)1.0 (0.8-1.3)1.1 (0.9-1.4)1.1 (0.9-1.4)p = 0.221.01 (1.00-1.02)	12 (31)7 (18)7 (18)13 (33)	1.0 (ref)0.6 (0.2-1.5)0.6 (0.2-1.5)1.0 (0.5-2.3)p = 0.911.00 (0.95-1.05)	15 (19)17 (22)21 (27)24 (31)	1.0 (ref)1.1 (0.5-2.3)1.4 (0.7-2.8)1.5 (0.7-2.8)p = 0.211.03 (1.00-1.06)





	Controls	Luminal cases	HER2-overexpressing cases	Triple-negative cases
	n (%)	n (%)	OR* (95% CI)	n (%)	OR* (95% CI)	n (%)	OR* (95% CI)
Weight at age 30, lbs   Quartiles: <120                   120-128                   129-140                   > 140Trend test   Continuous (per lb):	389 (27)367 (25)323 (22)368 (25)	263 (26)215 (21)270 (27)260 (26)	1.0 (ref)0.9 (0.7-1.1)1.2 (1.0-1.5)1.1 (0.8-1.3)p = 0.221.00 (0.99-1.01)	15 (38)8 (21)6 (15)10 (26)	1.0 (ref)0.6 (0.2-1.4)0.5 (0.2-1.2)0.7 (0.3-1.6)p = 0.310.99 (0.96-1.03)	20 (26)12 (16)16 (21)29 (38)	1.0 (ref)0.7 (0.3-1.5)0.9 (0.5-1.8)1.5 (0.8-2.7)p = 0.111.01 (1.00-1.03)
BMI at age 30, kg/m2   Quartiles: < 20.8                    20.8-22.3                    22.4-24.3                    > 24.3Trend test   Continuous (per kg/m2):	362 (25)361 (25)362 (25)362 (25)	258 (26)233 (23)279 (28)238 (24)	1.0 (ref)0.9 (0.7-1.2)1.1 (0.9-1.4)0.9 (0.8-1.2)p = 0.911.00 (0.97-1.02)	11 (28)9 (23)6 (15)13 (33)	1.0 (ref)0.8 (0.3-2.0)0.6 (0.2-1.6)1.2 (0.5-2.8)p = 0.740.99 (0.90-1.08)	21 (27)18 (23)11 (14)27 (35)	1.0 (ref)0.9 (0.5-1.7)0.6 (0.3-1.2)1.4 (0.8-2.5)p = 0.411.03 (0.98-1.09)
Weight change (age 30 vs. reference, lbs)Overall   Weight loss   Weight gain (tertiles):  < 18                                       18-37                                       > 37   Continuous (per lb):	201 (14)407 (28)416 (29)423 (29)	71 (7)320 (32)289 (29)328 (33)	0.5 (0.3-0.6)†1.0 (ref)0.9 (0.7-1.1)1.0 (0.8-1.2)1.00 (1.00-1.01)†	3 (8)13 (33)10 (26)13 (33)	0.5 (0.1-1.8)1.0 (ref)0.7 (0.3-1.7)0.9 (0.4-2.0)1.01 (0.99-1.02)	9 (12)20 (26)25 (32)23 (30)	1.1 (0.5-2.4)1.0 (ref)1.1 (0.6-2.0)1.0 (0.5-1.8)1.00 (0.99-1.01)
* Odds ratio (OR) adjusted for age and reference year.
† p<0.05.





